Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients

NCT04348006 is registered in ClinicalTrials.gov with Al-Rasheed University College as lead sponsor.

NCT NCT04348006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04348006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients
Lead sponsor
Al-Rasheed University College
Phase
Phase 4
Overall status
Withdrawn
Start date
March 1, 2020
Completion date
July 30, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed multiple myeloma